Robotic biliary surgery for benign and malignant bile duct obstruction: a case series.

J Robot Surg

Department of Abdominal and Hepatobiliary/Pancreatic Surgery, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600, Genk, Belgium.

Published: February 2023

The majority of patients with benign or malignant biliary obstruction require surgical treatment with a bilio-enteric anastomosis. This requires fine dissection and advanced suturing. Robotic surgery may overcome some major limitations of conventional laparoscopic surgery. The precise role of robotic biliary surgery is, however, still to be defined. In our institution, patients requiring complex bile duct surgery were consecutively selected for minimally invasive robotic surgery from September 2020. All surgeries were undertaken using the da Vinci Xi Surgical System (Intuitive Surgical, Sunnyvale, CA, USA). Intra-operative technique and postoperative outcome were analyzed. A total number of 14 patients underwent robotic biliary surgery for a variety of benign and malignant indications between September 2020 and May 2021. Six of fourteen patients (43%) had previous open abdominal surgery. Median blood loss was 25 mL (range 10-120 mL). There were no intra-operative complications and no conversions. Length of stay was between 3 and 11 days without major postoperative morbidity. Robotic surgery for benign and malignant bile duct obstruction is efficient and safe in experienced hands. Referral to a high-volume expert center is, however, advised.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11701-022-01392-yDOI Listing

Publication Analysis

Top Keywords

benign malignant
16
robotic biliary
12
biliary surgery
12
bile duct
12
robotic surgery
12
surgery
9
surgery benign
8
malignant bile
8
duct obstruction
8
september 2020
8

Similar Publications

Background: Perivascular epithelioid cell tumors (PEComas) rarely appear in the head and neck region. This case report describes two transcription factor E3 (TFE3)-rearranged PEComa cases, consisting of one in the orbit and one in the nasal cavity.

Case Presentation: Both cases demonstrated sheet-like or focal nested architecture and comprised epithelioid cells with abundant clear to eosinophilic cytoplasm and vascular stroma.

View Article and Find Full Text PDF

Clinical characteristics and laparoscopic management experience of primary ovarian leiomyoma.

Sci Rep

January 2025

Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Primary leiomyoma is one of the rarest benign ovarian tumors. Since the first case was identified, less than 100 cases have been reported worldwide. This study aimed to analyze the clinical characteristics and discuss the proper management of this tumor.

View Article and Find Full Text PDF

Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?

Expert Rev Anticancer Ther

January 2025

Department of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.

Small renal masses (SRM), especially those under 7 cm pose significant diagnostic challenges when using conventional imaging (CT/MRI). PET/CT with [Zr]Zr-girentuximab offers a promising alternative in this setting by enabling molecular-level imaging. The ZIRCON trial, a phase 3 multicenter study, evaluated the diagnostic accuracy of [Zr]Zr-girentuximab PET/CT in detecting clear cell renal cell carcinoma (ccRCC) in SRM.

View Article and Find Full Text PDF

Clear cell hidradenoma of the male breast: A case report and literature review.

Int J Surg Case Rep

January 2025

Department of Pathology, The First Affiliated Hospital of Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, Zhejiang 310003, China. Electronic address:

Introduction: Clear cell hidradenoma (CCH) is a rare type of benign breast tumor that may undergo malignant transformation in a few cases. It clinically manifests as a painless breast mass, and may include nipple discharge. Complete surgical excision with adequate safety margins is the primary treatment.

View Article and Find Full Text PDF

Giant cell tumors (GCTs) are benign but locally aggressive bone neoplasms that primarily affect skeletally mature individuals. They are characterized by a tendency for recurrence and being associated with significant morbidity. Traditional treatment has focused on surgical resection; however, the role of medical therapies, such as Denosumab, a bone anti-resorptive drug, which has been Food and Drug Administration (FDA)-approved for unresectable GCTs since 2013, recently has gained prominence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!